Search

Author/Creator Cutter, Gary

1. 036  Ocrelizumab real-world effectiveness in patients with relapsing and primary progressive multiple sclerosis: MuSicalE baseline data. Issue 6 (27th May 2022)

Authors:
Hobart, Jeremy; Pesch, Vincent van; Rovira, Alex; Alroughani, Raed; Cutter, Gary; Craveiro, Licinio; Dzhenkova, Dima; Kuenzel, Thomas; Kantaria, Rakesh; Trojano, Maria
Journal:
Journal of neurology, neurosurgery and psychiatry
Issue:
Volume 93:Issue 6(2022)
Page Start:
A24
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 071 Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch® prescribing program. Issue 6 (24th May 2018)

Authors:
Ryerson, Lana Zhovtis; Foley, John; Chang, Ih; Kister, Ilya; Cutter, Gary; Metzger, Ryan; Goldberg, Judith D; Li, Xiaochun; Riddle, Evan; Smirnakis, Karen; Yu, Bei; Ren, Zheng; Hotermans, Christophe; Ho, Pei-Ran; Campbell, Nolan
Journal:
Journal of neurology, neurosurgery and psychiatry
Issue:
Volume 89:Issue 6(2018)
Page Start:
A29
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 136 NOVA primary results randomised controlled study of natalizumab Q6W versus continued Q4W treatment for MS. Issue 9 (12th August 2022)

Authors:
Foley, John; Defer, Gilles; Ryerson, Lana Zhovtis; Cohen, Jeffrey; Arnold, Douglas; Butzkueven, Helmut; Cutter, Gary; Giovannoni, Gavin; Killestein, Joep
Journal:
Journal of neurology, neurosurgery and psychiatry
Issue:
Volume 93:Issue 9(2022)
Page Start:
e2
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS. (5th March 2019)

Authors:
Nelson, Lorene M.; Wallin, Mitchell T.; Marrie, Ruth Ann; Culpepper, W.J.; Langer-Gould, Annette; Campbell, Jon; Buka, Stephen; Tremlett, Helen; Cutter, Gary; Kaye, Wendy; Wagner, Laurie; Larocca, Nicholas G.
Journal:
Neurology
Issue:
Volume 92:Number 10(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Issue 10 (1st April 2020)

Authors:
Ullrich, Nicole J; Prabhu, Sanjay P; Reddy, Alyssa T; Fisher, Michael J; Packer, Roger; Goldman, Stewart; Robison, Nathan J; Gutmann, David H; Viskochil, David H; Allen, Jeffrey C; Korf, Bruce; Cantor, Alan; Cutter, Gary; Thomas, Coretta; Perentesis, John P; Mizuno, Tomoyuki; Vinks, Alexander A; ...
Journal:
Neuro-oncology
Issue:
Volume 22:Issue 10(2020)
Page Start:
1527
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗